{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:40:53Z","timestamp":1761709253889,"version":"3.28.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Ministerio de Educaci\u00f3n y Ciencia, Spain"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Elevated levels of angiotensin II are implicated in the hypertensive pathophysiological process. Zofenopril has a sulphydryl group which gives it antioxidant properties. The aim of this study was to investigate its beneficial effects beyond angiotensin-converting enzyme (ACE) inhibition using angiotensin II-infused rats as hypertension model.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Zofenopril was added in drinking water. Systolic blood pressure was assessed by the tail-cuff method. Left ventricular weight\/body weight ratio was calculated as cardiac hypertrophy index. An estimate of the cardiac collagen was performed by measuring the content of hydroxyproline. Vascular reactivity was evaluated on aortic rings and isolated perfused kidney, and vascular structure in thoracic aorta was studied. Superoxide anion generation was quantified in aorta by lucigenin-enhanced chemiluminescence.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Key findings<\/jats:title>\n                  <jats:p>Zofenopril partially prevented the increase in systolic blood pressure and cardiac hypertrophy induced by angiotensin II and avoided the increase in collagen deposition. The treatment improved vasorelaxing responses, reversed the vascular remodelling and abolished the effects of angiotensin II on the production of O2\u2212. It is worth to mention that all these results are observed even with high levels of plasma angiotensin.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Zofenopril could exert additional beneficial effects beyond ACE inhibition that would justify the improvement of pathophysiological processes triggered by angiotensin II.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1111\/jphp.12641","type":"journal-article","created":{"date-parts":[[2016,9,27]],"date-time":"2016-09-27T05:27:42Z","timestamp":1474954062000},"page":"1422-1429","source":"Crossref","is-referenced-by-count":3,"title":["Zofenopril exerts a cardiovascular protective effect on rats infused with angiotensin II beyond angiotensin-converting enzyme inhibition"],"prefix":"10.1093","volume":"68","author":[{"given":"Miriam","family":"G\u00f3mez-Roso","sequence":"first","affiliation":[{"name":"Department of Physiology and Pharmacology, Faculty of Pharmacy, University of Salamanca , Salamanca,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda J","family":"Montero","sequence":"additional","affiliation":[{"name":"Department of Physiology and Pharmacology, Faculty of Pharmacy, University of Salamanca , Salamanca,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosal\u00eda","family":"Carr\u00f3n","sequence":"additional","affiliation":[{"name":"Department of Physiology and Pharmacology, Faculty of Pharmacy, University of Salamanca , Salamanca,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda A","family":"Sevilla","sequence":"additional","affiliation":[{"name":"Department of Physiology and Pharmacology, Faculty of Pharmacy, University of Salamanca , Salamanca,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2016,11,1]]},"reference":[{"key":"2024103012541734400_jphp12641-cit-0001","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S0140-6736(77)92958-0","article-title":"A specific orally active inhibitor of angiotensin-converting enzyme in man","volume":"1","author":"Ferguson","year":"1977","journal-title":"Lancet"},{"key":"2024103012541734400_jphp12641-cit-0002","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/j.1751-7176.2011.00508.x","article-title":"Angiotensin-converting enzyme inhibitors","volume":"13","author":"Izzo","year":"2011","journal-title":"J Clin Hypertens"},{"key":"2024103012541734400_jphp12641-cit-0003","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1111\/j.1476-5381.2009.00491.x","article-title":"Cardiovascular changes in spontaneously hypertensive rats are improved by chronic treatment with zofenopril","volume":"158","author":"G\u00f3mez-Roso","year":"2009","journal-title":"Br J Pharmacol"},{"key":"2024103012541734400_jphp12641-cit-0004","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/eurheartj\/ehr400","article-title":"Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are beneficial in normotensive atherosclerotic patients: a collaborative meta-analysis of randomized trials","volume":"33","author":"McAlister","year":"2012","journal-title":"Eur Heart J"},{"key":"2024103012541734400_jphp12641-cit-0005","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.lfs.2004.04.004","article-title":"Amlodipine decreases fibrosis and cardiac hypertrophy in spontaneously hypertensive rats: persistent effects after withdrawal","volume":"75","author":"Sevilla","year":"2004","journal-title":"Life Sci"},{"key":"2024103012541734400_jphp12641-cit-0006","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/nm1426","article-title":"Vav3 proto-oncogene deficiency leads to sympathetic hyperactivity and cardiovascular dysfunction","volume":"12","author":"Sauzeau","year":"2006","journal-title":"Nat Med"},{"key":"2024103012541734400_jphp12641-cit-0007","doi-asserted-by":"crossref","first-page":"e111117","DOI":"10.1371\/journal.pone.0111117","article-title":"An interaction of renin-angiotensin and kallikrein-kinin systems contributes to vascular hypertrophy in angiotensin II-induced hypertension: in vivo and in vitro studies","volume":"9","author":"Ceravolo","year":"2014","journal-title":"PLoS One"},{"key":"2024103012541734400_jphp12641-cit-0008","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.phrs.2008.06.009","article-title":"Local RAS and inflammatory factors are involved in cardiovascular hypertrophy in spontaneously hypertensive rats","volume":"58","author":"Li","year":"2008","journal-title":"Pharmacol Res"},{"key":"2024103012541734400_jphp12641-cit-0009","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0167-5273(01)00539-3","article-title":"Diverse effects of chronic treatment with losartan, fosinopril, and amlodipine on apoptosis, angiotensin II in the left ventricle of hypertensive rats","volume":"81","author":"Yu","year":"2001","journal-title":"Int J Cardiol"},{"key":"2024103012541734400_jphp12641-cit-0010","first-page":"169","article-title":"Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension","volume":"50","author":"Palmieri","year":"2002","journal-title":"Minerva Cardioangiol"},{"key":"2024103012541734400_jphp12641-cit-0011","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1161\/CIRCULATIONAHA.113.001878","article-title":"Pathological ventricular remodeling: mechanisms: part 1 of 2","volume":"128","author":"Burchfield","year":"2013","journal-title":"Circulation"},{"key":"2024103012541734400_jphp12641-cit-0012","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0008-6363(99)00432-0","article-title":"Regression of myocardial fibrosis in hypertensive heart disease: diverse effects of various antihypertensive drugs","volume":"46","author":"Brilla","year":"2000","journal-title":"Cardiovasc Res"},{"key":"2024103012541734400_jphp12641-cit-0013","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1161\/01.CIR.96.11.4002","article-title":"Effect of angiotensin-converting enzyme inhibition on myocardial fibrosis and function in hypertrophied and failing myocardium from the spontaneously hypertensive rat","volume":"96","author":"Brooks","year":"1997","journal-title":"Circulation"},{"key":"2024103012541734400_jphp12641-cit-0014","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1177\/147323000503300103","article-title":"Antioxidant and cardioprotective properties of the sulphydryl angiotensin-converting enzyme inhibitor zofenopril","volume":"33","author":"Evangelista","year":"2005","journal-title":"J Int Med Res"},{"key":"2024103012541734400_jphp12641-cit-0015","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ijcard.2003.10.016","article-title":"Diverse effects of Ace inhibitors and angiotensin II receptor antagonists on prevention of cardiac hypertrophy and collagen distribution in spontaneously hypertensive rats","volume":"97","author":"Gagnon","year":"2004","journal-title":"Int J Cardiol"},{"key":"2024103012541734400_jphp12641-cit-0016","doi-asserted-by":"crossref","first-page":"e003531","DOI":"10.1161\/JAHA.116.003531","article-title":"Zofenopril protects against myocardial ischemia-reperfusion injury by increasing nitric oxide and hydrogen sulfide bioavailability","volume":"5","author":"Donnarumma","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"2024103012541734400_jphp12641-cit-0017","first-page":"27","article-title":"Zofenopril avoids cardiovascular alterations in angiotensin II infused mice","volume":"2","author":"G\u00f3mez-Roso","year":"2014","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2024103012541734400_jphp12641-cit-0018","first-page":"808353","article-title":"Pathophysiology of vascular remodeling in hypertension","volume":"2013","author":"Renna","year":"2013","journal-title":"Int J Hypertens"},{"key":"2024103012541734400_jphp12641-cit-0019","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1161\/01.HYP.32.3.452","article-title":"Pressure mediates angiotensin II-induced arterial hypertrophy and PDGF-A expression","volume":"32","author":"Parker","year":"1998","journal-title":"Hypertension"},{"key":"2024103012541734400_jphp12641-cit-0020","doi-asserted-by":"crossref","first-page":"916310","DOI":"10.4061\/2011\/916310","article-title":"Oxidative stress and vascular damage in hypertension: role of angiotensin II","volume":"2011","author":"Virdis","year":"2011","journal-title":"Int J Hypertens"},{"key":"2024103012541734400_jphp12641-cit-0021","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s11906-014-0431-2","article-title":"Angiotensin II and vascular injury","volume":"16","author":"Montezano","year":"2014","journal-title":"Curr Hypertens Rep"},{"key":"2024103012541734400_jphp12641-cit-0022","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1126\/science.294.5548.1871","article-title":"Prostaglandins and leukotrienes: advances in eicosanoid biology","volume":"294","author":"Funk","year":"2001","journal-title":"Science"},{"key":"2024103012541734400_jphp12641-cit-0023","doi-asserted-by":"crossref","first-page":"1154.e1","DOI":"10.1016\/j.ahj.2008.09.006","article-title":"Long-term treatment with sulfhydryl angiotensin-converting enzyme inhibition reduces carotid intima-media thickening and improves the nitric oxide\/oxidative stress pathways in newly diagnosed patients with mild to moderate primary hypertension","volume":"156","author":"Napoli","year":"2008","journal-title":"Am Heart J"},{"key":"2024103012541734400_jphp12641-cit-0024","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1093\/cvr\/cvu026","article-title":"Hydrogen sulfide accounts for the peripheral vascular effects of zofenopril independently of ACE inhibition","volume":"102","author":"Bucci","year":"2014","journal-title":"Cardiovasc Res"}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjphp.12641","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjphp.12641","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/68\/11\/1422\/60229675\/jphp12641.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/68\/11\/1422\/60229675\/jphp12641.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T18:20:07Z","timestamp":1730312407000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/68\/11\/1422\/6128288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,1]]},"references-count":24,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2016,11,1]]},"published-print":{"date-parts":[[2016,11,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jphp.12641","relation":{},"ISSN":["2042-7158","0022-3573"],"issn-type":[{"type":"electronic","value":"2042-7158"},{"type":"print","value":"0022-3573"}],"subject":[],"published-other":{"date-parts":[[2016,11]]},"published":{"date-parts":[[2016,11,1]]}}}